Company intelligence / Profile preview

Thrasos Therapeutics

Montreal, Quebec, Canadapmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Other

Overview

Thrasos Therapeutics is a private, clinical-stage biotherapeutics company developing peptide-based drugs to treat and prevent acute kidney injury and slow or reverse the progression of diabetic nephropathy. Their lead candidate, THR‑184, has shown promising results in preclinical and early clinical studies for protecting, repairing, and restoring renal function by modulating apoptosis, inflammation, and fibrosis. The company’s proprietary peptides have demonstrated efficacy in experimental models of both AKI and CKD.

Therapeutic areas: Nephrology
Modalities: PeptidesSmall molecule (lead candidates are orally active)
Industry: Biotech

Partnerships

No major pharmaceutical partnerships publicly disclosed as of latest available data.

Beyond the preview

Go deeper on Thrasos Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Thrasos Therapeutics.

Explore the full profile